Company Overview
Optomed was founded in 2004 and is headquartered in Oulu, Finland. The company has since grown to become a leading player in the global eye care market, with operations in multiple countries and a strong reputation for innovation and excellence.
The company's management team includes experienced professionals with a deep understanding of the healthcare technology industry. With a focus on customer-centricity and a commitment to delivering exceptional products and services, Optomed is well-positioned for continued growth and success in the years to come.
Optomed is a Finnish-based healthcare technology company that specializes in developing innovative solutions for eye care and vision correction. With its cutting-edge technology, the company aims to improve the lives of millions of people worldwide by providing high-quality diagnostic tools and treatment options.
The primary mission of Optomed is to revolutionize eye care by leveraging advanced technologies such as artificial intelligence, machine learning, and computer vision. The company's core values include innovation, customer-centricity, and excellence in everything it does. By staying at the forefront of technological advancements, Optomed strives to deliver exceptional products and services that exceed its customers' expectations.
Key Products/Services
Optomed offers a range of innovative products and services that cater to the growing demand for eye care solutions. Some of its key offerings include:
- Fundus cameras: Optomed's handheld fundus cameras are designed to provide high-quality, non-invasive imaging of the retina, enabling early detection and treatment of eye diseases.
- AI-powered diagnostic: The company's AI-powered diagnostic tools use machine learning algorithms to analyze images and detect abnormalities in the retina, allowing for more accurate diagnoses and personalized treatment plans.
- Equipment and software: Optomed provides a range of diagnostic equipment and software solutions that cater to different needs and applications in eye care.
Benefits
The benefits of using Optomed's products and services include:
- Improved accuracy and speed: Optomed's AI-powered diagnostic tools enable faster and more accurate diagnoses, reducing the risk of misdiagnosis and improving patient outcomes.
- Enhanced patient experience: The company's innovative products and services are designed to provide a comfortable and stress-free experience for patients, making eye care more accessible and convenient.
- Increased efficiency and productivity: Optomed's solutions help eye care professionals streamline their workflows, reduce administrative burdens, and focus on providing high-quality patient care.
Valuation
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Number of Shares (million) | 16.5 | 18.1 | 19.7 | 21.5 | 21.5 | 21.5 | 21.5 |
| Target Valuation (MEur) | 8.0 | 8.2 | 6.7 | 4.7 | 4.7 | 0.8 | 0.8 |
| Targer Price | 0.49 | 0.45 | 0.34 | 0.22 | 0.22 | 0.04 | 0.04 |
| Potential, % | -87.1 | -87.8 | -92.7 | -94.2 | -86.7 | -97.7 | -97.7 |
| Recommendation | Sell | Sell | Sell | Sell | Sell | Sell | Sell |
| MCAP (MEur) | 61.9 | 67.4 | 91.8 | 80.9 | 35.3 | 35.3 | 35.3 |
| Price | 3.74 | 3.72 | 4.66 | 3.77 | 1.65 | 1.65 | 1.65 |
| EV | 59.0 | 64.0 | 84.0 | 72.0 | 33.0 | 40.0 | 48.0 |
| P/S | 4.23 | 4.46 | 6.1 | 4.73 | 2.26 | 1.81 | 1.6 |
| EV/S | 4.0 | 4.21 | 5.56 | 4.24 | 2.13 | 2.04 | 2.2 |
| EV/EBIT | -11.52 | -16.01 | -14.03 | -11.98 | -5.93 | -5.29 | -5.14 |
| P/E | -11.28 | -15.1 | -16.84 | -12.18 | -7.85 | -5.87 | -4.69 |
| P/B | 3.05 | 3.31 | 3.88 | 3.37 | 1.82 | 2.65 | 6.08 |
| P/OCF | -27.34 | -112.63 | -41.88 | -33.07 | -13.25 | -15.4 | -7.96 |
| EV/OCF | -25.9 | -106.33 | -38.16 | -29.6 | -12.48 | -17.35 | -10.92 |
| P/FCF | -11.68 | -22.38 | -21.42 | -16.86 | -7.39 | -7.95 | -5.36 |
| EV/FCF | -11.07 | -21.13 | -19.51 | -15.09 | -6.96 | -8.96 | -7.36 |
Income Statement
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Revenue | 14.7 | 15.1 | 15.0 | 17.1 | 15.6 | 19.5 | 22.0 |
| Rev. Growth, % | -0.7 | 2.7 | -0.7 | 14.0 | -8.8 | 25.0 | 12.8 |
| Ebit | -5.1 | -4.0 | -6.0 | -6.0 | -5.6 | -7.5 | -9.4 |
| Ebit Growth, % | -6.2 | 21.6 | -50.0 | -0.0 | 6.7 | -33.9 | -25.3 |
| Ebit, % | -34.7 | -26.5 | -40.0 | -35.1 | -35.9 | -38.5 | -42.7 |
| Profit | -5.5 | -4.5 | -5.4 | -6.6 | -4.5 | -6.0 | -7.5 |
| EPS | -0.33 | -0.25 | -0.27 | -0.31 | -0.21 | -0.28 | -0.35 |
| Profit Growth, % | -31.0 | 18.2 | -20.0 | -22.2 | 31.8 | -33.3 | -25.0 |
| Profit, % | -37.4 | -29.8 | -36.0 | -38.6 | -28.8 | -30.8 | -34.1 |
Balance Sheet
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Inventory | 3.0 | 2.8 | 2.0 | 2.4 | 2.6 | 1.9 | 1.6 |
| Acc. Receivable | 4.6 | 3.2 | 3.3 | 3.5 | 2.9 | 2.0 | 2.1 |
| Cash | 8.5 | 7.1 | 10.5 | 9.9 | 3.4 | -3.1 | -11.8 |
| Equity | 20.3 | 20.4 | 23.6 | 24.0 | 19.3 | 13.3 | 5.8 |
| ROE, % | -27.1 | -22.1 | -22.9 | -27.5 | -23.3 | -45.1 | -129.3 |
| ROCE, % | -19.9 | -16.8 | -23.2 | -23.6 | -27.2 | -51.3 | -132.0 |
| Net Debt | -3.3 | -3.8 | -8.2 | -8.5 | -2.0 | 4.5 | 13.1 |
| Gearing, % | -16.0 | -18.5 | -34.6 | -35.3 | -10.6 | 33.4 | 225.7 |
| Equity ratio, % | 65.0 | 70.0 | 74.4 | 75.1 | 64.7 | 44.8 | 19.2 |
| Acc. Payable | 3.8 | 3.6 | 4.1 | 5.1 | 6.5 | 10.3 | 15.8 |
| Total Assets | 31.3 | 29.1 | 31.8 | 32.0 | 29.9 | 29.7 | 30.2 |
| ROA, % | -17.6 | -15.5 | -17.0 | -20.6 | -15.1 | -20.2 | -24.8 |
Cash Flow
| 2022 | 2023 | 2024 | 2025 | 2026 (e) | 2027 (e) | 2028 (e) | |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.3 | -0.6 | -2.2 | -2.4 | -2.7 | -2.3 | -4.4 |
| Investment Cash Flow | -3.0 | -2.4 | -2.1 | -2.4 | -2.1 | -2.1 | -2.1 |
| Free Cash Flow | -5.3 | -3.0 | -4.3 | -4.8 | -4.8 | -4.4 | -6.6 |
| OCF/CAPEX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial Cash Flow | 6.9 | 1.6 | 7.6 | 4.2 | -1.8 | -2.1 | -2.1 |
Disclaimer
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.
Contact: quant@quantfactory.eu